Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentoxifylline + platelet rich plasma
- Development stage
- Unknown
- Lead developer
- Sohag University
- Modality
- Small Molecules
- Administration
- Intralesional
01
Overview
A combination therapy consisting of intralesional pentoxifylline and autologous platelet-rich plasma (PRP) investigated for the treatment of atrophic acne scars. Pentoxifylline is a methylxanthine derivative that functions as a nonselective phosphodiesterase inhibitor, enhancing microcirculation and exerting anti-fibrotic effects by modulating cytokine activity and reducing collagen production in certain contexts, while promoting healthy tissue remodeling. Platelet-rich plasma is a concentrated autologous biologic containing various growth factors, including PDGF, TGF-beta, and VEGF, which promote tissue remodeling, angiogenesis, and collagen synthesis. This combination is designed to synergistically improve the appearance of icepick, boxcar, and rolling acne scars by stimulating the skin's natural healing and regenerative processes. The therapy is being evaluated in clinical trials sponsored by Sohag University.
- Brand names
- Trentoximal
- Other names
- PTX + PRPpentoxifylline and platelet-rich plasmaintralesional pentoxifylline and platelet-rich plasma
02
Targets
PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on pentoxifylline + platelet rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentoxifylline + platelet rich plasma.